Intriguingly, the active CDK4/Cyclin D/phospho(Tyr74)p27 complex is insensitive to palbociclib, a chemotherapeutic drug that selectively inhibits CDK4/6 and that has been recently introduced in the therapy of hormone receptor-positive (HR+)/HER- breast cancer [17]. The gene discussed is CDK4; the disease is breast carcinoma.